Atea Pharmaceuticals Inc
AVIR3.635USD
+0.165+4.76%
Market hours （ET）Quotes delayed by 15 min
311.08MMarket Cap
LossP/E TTM
More Details of Atea Pharmaceuticals Inc Company
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.
Company Info
Ticker SymbolAVIR
Company nameAtea Pharmaceuticals Inc
IPO dateOct 30, 2020
CEODr. Jean-Pierre Sommadossi, Ph.D.
Number of employees56
Security typeOrdinary Share
Fiscal year-endOct 30
Address225 Franklin Street
CityBOSTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02110
Phone18572048109
Websitehttps://ateapharma.com/
Ticker SymbolAVIR
IPO dateOct 30, 2020
CEODr. Jean-Pierre Sommadossi, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
Dr. Maria Arantxa Horga, M.D.
Dr. Maria Arantxa Horga, M.D.
Chief Medical Officer
Chief Medical Officer
60.88K
--
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
45.71K
+28.00%
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Janet Hammond, M.D., Ph.D.
Dr. Janet Hammond, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
Revenue Breakdown
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
8.89%
BlackRock Institutional Trust Company, N.A.
7.78%
Fidelity Management & Research Company LLC
7.03%
JPM Partner LLC
6.85%
Tang Capital Management, LLC
5.61%
Other
63.83%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
8.89%
BlackRock Institutional Trust Company, N.A.
7.78%
Fidelity Management & Research Company LLC
7.03%
JPM Partner LLC
6.85%
Tang Capital Management, LLC
5.61%
Other
63.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.29%
Investment Advisor/Hedge Fund
12.63%
Hedge Fund
9.43%
Corporation
6.85%
Individual Investor
4.94%
Family Office
3.95%
Research Firm
1.14%
Pension Fund
0.31%
Bank and Trust
0.15%
Other
21.32%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
264
65.24M
76.23%
-9.09M
2025Q1
301
65.12M
76.13%
-9.02M
2024Q4
315
66.52M
78.76%
-10.39M
2024Q3
317
68.18M
80.76%
-8.54M
2024Q2
318
67.11M
79.66%
-7.40M
2024Q1
325
64.40M
76.50%
-9.70M
2023Q4
340
64.58M
77.29%
-9.97M
2023Q3
373
64.87M
77.77%
-27.38M
2023Q2
383
65.08M
78.05%
-32.20M
2023Q1
380
65.62M
78.75%
-30.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
7.61M
8.89%
+1.50K
+0.02%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.66M
7.78%
-104.44K
-1.54%
Mar 31, 2025
Fidelity Management & Research Company LLC
6.02M
7.03%
-407.21K
-6.34%
Mar 31, 2025
JPM Partner LLC
5.87M
6.85%
--
--
Apr 22, 2025
Tang Capital Management, LLC
4.80M
5.61%
+11.09K
+0.23%
Mar 31, 2025
The Vanguard Group, Inc.
4.73M
5.52%
+60.85K
+1.30%
Mar 31, 2025
Radoff Family Foundation
3.38M
3.95%
+275.00K
+8.86%
Apr 16, 2025
Bain Capital Life Sciences Investors, LLC
2.49M
2.9%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.98M
2.31%
+60.55K
+3.16%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.77M
2.07%
-9.23K
-0.52%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
0.21%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.03%
Avantis US Small Cap Equity ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
View more
ALPS Medical Breakthroughs ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
